Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › hydroxyurea

hydroxyurea

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of hydroxyurea

26 trials tracked of hydroxyurea: 6 in phase 3 or 4 and 4 with published results. The most-cited published study has 789 citations.

26Trials tracked
6Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 5 Phase 2 18 Other / NA 2
  1. Phase 3 Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia Completed · 789 cited
  2. Phase 3 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed · 171 cited
  3. Phase 3 Novel Use Of Hydroxyurea in an African Region With Malaria Completed · 150 cited
  4. Phase 4 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed · 18 cited
  5. Phase 3 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed
  6. Phase 3 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed
Show 20 more trials
  1. Phase 2 HSCT for High Risk Inherited Inborn Errors Completed
  2. Phase 2 Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies Completed
  3. Phase 2 A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients Completed
  4. Phase 2 Hydroxyurea and EPO in Sickle Cell Disease Completed
  5. Phase 2 Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease Completed
  6. Phase 2 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed
  7. Phase 2 A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients Completed
  8. Phase 2 Selinexor (KPT-330) in Older Patients With Relapsed AML Completed
  9. Phase 2 Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Completed
  10. Phase 2 Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer Completed
  11. Phase 2 Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow Completed
  12. Phase 2 S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma Completed
  13. Phase 2 Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer Completed
  14. Phase 2 Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer Completed
  15. Phase 2 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer Completed
  16. Phase 2 Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease Completed
  17. Phase 2 Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) Completed
  18. Phase 2 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer Completed
  19. N/A Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol Completed
  20. N/A Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study) Completed

Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
Hematology Meta-analysis
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Frontiers May 29, 2026
Narrative review proposes phenotype-driven framework for managing myelofibrosis splenomegaly
Cardiology Sys. Review
Narrative review proposes phenotype-driven framework for managing myelofibrosis splenomegaly New combo strategies shrink spleens better than older treatments for myelofibrosis
This narrative review addresses the management of splenomegaly in patients with myelofibrosis. The authors synthesize evidence regarding eme…
Emerging combination strategies like pelabresib plus ruxolitinib or navitoclax plus ruxolitinib show superior spleen shrinkage for myelofibr…
Frontiers May 26, 2026
Systematic review identifies specific medications significantly associated with drug-induced hyperpigmentation across diverse drug classes
Drug Pipeline Meta-analysis
Systematic review identifies specific medications significantly associated with drug-induced hyperpigmentation across diverse drug classes These Common Meds Might Be Darkening Your Skin
A systematic review and meta-analysis evaluated twenty-two studies regarding the incidence of drug-induced hyperpigmentation.
A major review reveals many common medicines can cause noticeable skin darkening.
Frontiers Apr 24, 2026
Cross-Sectional Analysis of Cardiac Structure and Function in 57 Adults With Sickle Cell Disease
Cardiology Sys. Review
Cross-Sectional Analysis of Cardiac Structure and Function in 57 Adults With Sickle Cell Disease Heart Risk Found in Young Sickle Cell Patients
This observational, cross-sectional study assessed echocardiographic profiles in 57 adults with confirmed Sickle Cell Disease at a tertiary …
Young adults with sickle cell disease often show early signs of heart strain, explaining why some feel tired or short of breath even when ot…
medRxiv Apr 20, 2026
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts
Oncology RCT
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts Keeping Blood Cell Counts Low in Leukemia Predicts Who Lives Longer
This randomized controlled trial (RCT) enrolled 120 patients with advanced proliferative chronic myelomonocytic leukemia (CMML) comparing de…
In chronic myelomonacytic leukemia, keeping abnormal blood cells low after treatment predicts who lives longer than bone marrow changes alon…
Apr 18, 2026
POCUS-guided assessments and serial exchange transfusions improved outcomes in a 20-year-old male with sickle cell disease and acute chest syndrome
Cardiology Cohort
POCUS-guided assessments and serial exchange transfusions improved outcomes in a 20-year-old male with sickle cell disease and acute chest syndrome Bedside Ultrasound Saves Sickle Cell Lives
This single case report describes a 20-year-old male with HbSS, acute chest syndrome, and acute pulmonary hypertension managed in the ICU.
A simple ultrasound at the bedside can tell doctors exactly when a sickle cell patient needs another blood transfusion to save their life.
Frontiers Apr 16, 2026